Share

Information on Sartorius Stedim Biotech share (DIM) at a glance.

Stock Chart

Stock Chart

Share Overview

Share Overview

ISIN

FR0013154002

Stock exchange

Euronext Paris

Market segment

Local Securities - Compartment A (Large Caps)

Indixes

SBF 120 | CAC Next 20 | CAC Large 60 | CAC All-Tradable | CAC All Shares | CAC Healthcare | MSCI France | STOXX Europe 600

Capital stock

18,436,038 euros

Number of shares

92,180,190

- thereof Sartorius AG

73.6%

- thereof free float

26.4%

Voting rights

~161.0 million

- thereof Sartorius AG

~85.0%

- thereof free float

~15.0%

Sartorius Stedim Biotech is currently covered by 16 sell-side analysts. The following list shows their latest recommendations for Sartorius Stedim Biotech shares.


InstitutionAnalystDateTarget Price  Recommendation

JP Morgan

Richard Vosser

05.12.2023

280.00

Overweight

CIC Market Solutions 

Arnaud Cadart

28.11.2023

203.40

Neutral 

Morningstar

Jay Lee

16.11.2023

240.00

--

Kepler Chevreux

Oliver Reinberg

13.11.2023

215.00

Buy

Morgan Stanley

--

03.11.2023

220.00

Equal-weight

Berenberg 

Odysseas Manesiotis

27.10.2023

226.00

Buy

Barclays 

Charles Pitman

24.10.2023

185.00

Equalweight 

HSBC

Sezgi Özener

24.10.2023

240.00

Buy

Intron Health 

Naresh Chouhan

20.10.2023

165.00

Sell

Jefferies 

James Vane-Tempest

19.10.2023

240.00

Buy

Exane

Hugo Solvet

19.10.2023

300.00

Outperform

Societe Generale

Delphine Le Louët

16.10.2023

175.00

Sell

UBS

Colin White

13.10.2023

390.00

Buy

Oddo BHF

Oliver Metzger

13.10.2023

206.00

Hold

Gilbert Dupont 

Guillaume Cuvillier 

19.06.2023

280.00

Buy

Disclaimer

The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.

Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.

Sartorius Stedim Biotech S.A.’s issued capital amounted to €18.4 million as of February 28, 2022, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 160,522,434 voting rights as of the reporting date.

As of February 28, 2022, Sartorius AG holds 73.6% of the share capital and 84.6% of the outstanding voting rights. The remaining 26.4% of the shares are in free float; corresponding to 15.4% of the outstanding voting rights.